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Do Intraindividual Variation in Disease
Progression and the Ensuing Tight
Window of Opportunity Affect
Estimation of Screening Benefits?
Hendrik Koffijberg, PhD, Gabriel Rinkel, MD, Erik Buskens, PhD, MD
Modern diagnostic tools allow accurate assess-ment of the stage of a disease at a particular
moment in time. In modeling studies on the effects
of screening and intervention after detection of dis-
ease, often an overall steady or linear disease pro-
gression is assumed. Models are generally based on
an average rate of transition between different stages
of the disease.1, 2 However, diseases may progress at
different speeds in different individuals. This differ-
ence in disease progression between individuals
(interindividual variation) leads to a heterogeneous
population. Not taking into account this heterogene-
ity may affect the validity of the results of regression
models and decision analytical models on the effec-
tiveness of screening36 and may even affect the re-
sults of trials when benefits from treatment depend
on disease progression rates.7
In addition to differences in disease progression
between individuals, disease progression within in-
dividuals may vary over time. Examples of intrain-
dividual variation in progression over time are the
Background. The effects of variation in disease progres-
sion between individuals on the effectiveness of screening
have been assessed extensively in the literature. For sever-
al diseases, progression may also vary within individuals
over time. The authors study the effects of intraindividual
variation and the combined effects of inter- and intraindi-
vidual variation in disease progression on the effective-
ness of screening. Methods. The authors investigated the
risk reduction of aneurysmal subarachnoid hemorrhage
(SAH) achieved by screening for intracranial aneurysms
in a simulation study as a function of the inter- and
intraindividual variation in the risk of aneurysm rupture.
They also extended a previously constructed Markov mod-
el for the cost-effectiveness analysis of screening for new
aneurysms in patients with clipped aneurysms after SAH.
A time-varying risk of aneurysm rupture was introduced,
and the influence of this variation on cost-effectiveness
was assessed. Results. The risk reduction provided by
screening decreased with increasing intraindividual varia-
tion in disease progression. The expected number of pre-
vented instances of SAH was overestimated by 58% in
this simulation study when high degrees of inter- and
intraindividual variation were present. Interindividual var-
iation alone resulted in up to 33% overestimation and
intraindividual variation in up to 43% overestimation. In
the extended Markov model, screening benefits were over-
estimated by 24% when a high degree of intraindividual
variation was present but ignored. Conclusions. If intrain-
dividual variation in disease progression is ignored in deci-
sion models, subsequent cost-effectiveness analyses of
screening strategies will overestimate the benefits provided
by screening. This bias is comparable to, but partially inde-
pendent of, the bias caused by ignoring interindividual het-
erogeneity. Key words: disease progression; heterogeneity;
cost-effectiveness analysis; simulation. (Med Decis Mak-
ing 2009;29:82–90)
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staccato growth of abdominal aortic aneurysms and
intracranial aneurysms,8,9 sudden changes in pro-
gression of atherosclerosis,10 and heterogeneity in
metastatic prostate carcinoma.11 This intraindivi-
dual variation in disease progression over time may
affect the results of decision models. Decision mod-
els generally assume constant progression or risks.
Simple calculations are used to transform the long-
term rates observed to yearly risks. Clearly, such
recalculated annual risks ignore any variability in
disease progression between and within individuals
over time. As a result, in reality, fewer events may
be prevented than predicted using a constant risk
assumption. We hypothesize that not only interindi-
vidual variability but also intraindividual variation
in risk over time may negatively affect the model-
based estimations of health gains. We study the
effects of inter- and intraindividual variation in dis-
ease progression over time in a simulation study on
the effectiveness of screening and preventive treat-
ment for intracranial aneurysms in terms of reducing
instances of aneurysmal subarachnoid hemorrhage
(SAH) due to aneurysmal rupture. Also, we incorpo-
rate inter- and intraindividual variation in disease
progression in a previously developed Markov model
to reassess the cost-effectiveness of screening for new
aneurysms in patients who had an intracranial aneur-
ysm clipped after SAH.12 Originally, for this Markov
model, a constant risk of aneurysm growth and
aneurysm rupture had been assumed.9,13,14
METHODS
Simulation Study
In a simulation study on intracranial aneurysm
growth and rupture, we investigated the effect of
variation in risk of rupture within and between indi-
viduals on the efficacy of screening (i.e., the reduc-
tion in instances of SAH) for 8 different screening
strategies. A time horizon of 25 years was used, and
a hypothetical cohort of 100,000 women, aged 50 at
entry in the model and all having survived a previ-
ous episode of SAH, was simulated. This starting
age was similar to the age at entry in the previously
developed ASTRA decision model.12 Women have
a higher risk of SAH than do men, and the risk of
SAH is higher for individuals older than 60 than for
individuals younger than that age.15,16 In addition,
the risk of SAH is increased in patients with previ-
ous SAH.17 Within our time horizon, women aged
50 at entry in the model thus constitute a relevant
high-risk group because they are at risk of develop-
ing new aneurysms that may rupture later in life
(e.g., when the patients are older than 60 years
of age). The assumed combined annual risks of
aneurysm formation and aneurysm rupture resulted
in an estimated cumulative risk of SAH of 10.2% for
an individual after 25 years. Competing mortality
was taken into account in this risk estimation. With-
out any screening, the expected number of SAH
instances in our hypothetical cohort would therefore
be 10,200. An individual’s risk of rupture was deter-
mined by constructing a risk profile describing the
risk of rupture for each subsequent day of the 25-year
period covered. These risk profiles were constructed
based on 2 parameters: the within-individual varia-
tion of risk over time (WIV, or intraindividual varia-
tion) and the between-individual variation of risk
(BIV, or interindividual variation). Increasing values
of WIV result in more irregular, chaotic risk profiles,
and increasing values of BIV result in more individu-
als at high risk and at low risk of disease.
We investigated 3 categories of values for WIV
and BIV separately: no variation, low variation, and
high variation. The overall risk of aneurysm rupture
was dependent on a risk based on aneurysm growth
and a risk based on aneurysm size; each factor was
set to account for 50% of the total risk. The average
25-year risk of aneurysm rupture in our hypothetical
cohort was fixed (i.e., standardized to 10.2%) and
therefore the same for all combinations of BIV and
WIV values. The profile of rupture risk based on size
was determined by the rate and duration of aneur-
ysm growth, and thus it was the cumulative of the
growth-related risk profile. Details of the compila-
tion of risk profiles are given in the appendix.
For each screening strategy, we defined a screening
interval in years, a detection threshold comprising
the cumulative risk of rupture individuals must have
experienced before an aneurysm can be detected, and
a risk-free period after treatment in years. The detec-
tion threshold in reality is largely determined by
aneurysm size.18 Because no detailed information is
available on aneurysm growth rates, modeling of
changes over time in the distribution of aneurysm
sizes in a study population is infeasible. Therefore,
our model does not account for actual aneurysm size
but instead is based on risk of aneurysm rupture. We
therefore defined the detection threshold as the mini-
mum amount of absolute risk of rupture experienced
by an individual that would allow the aneurysm to be
detected. We assumed that aneurysms exceeding the
detection threshold would always be detected and
that detected aneurysms would always be treated.
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The risk-free period was defined as the period after
aneurysm treatment in which the risk of formation
and rupture was zero. Eight screening strategies were
defined, with screening intervals of 2 years or 5 years,
detection thresholds of 1% or 3% absolute risk, and a
risk-free period of 1 year or 2 years. Random draws
from the possible characteristics yielded a specific
risk profile for each hypothetical individual in the
cohort. The expected health benefit of the screening
strategies was calculated as the sum of the expected
risk reductions for all individuals. A visualization of
the screening process, for 3 hypothetical individuals,
is given in Figure 1. During the first screening exami-
nation, no aneurysm was detected for individual 3
Figure 1 Exemplary risk profiles of aneurysm rupture with the corresponding risk reduction offered by screening. Three examples of
risk profiles for individuals. The original growth-related and size-related risk profiles are shown in A and B, and the corresponding risk
profiles after screening are shown in C and D. The vertical lines in C and D show the screening moments and the end of the risk-free peri-
od after each screening moment. Here the screening interval was 7 years, the detection threshold was 1%, and the risk-free period was 2
years. The 3 individuals experience the same total risk of subarachnoid hemorrhage before screening (i.e., there is no interindividual var-
iation). No variation of risk over time is assumed for individual 1, a small variation is assumed for individual 2, and a high variation over
time is assumed for individual 3. In this example, the relative risk reduction provided by screening and preventive treatment is 54.4% for
individual 1, 41.8% for individual 2, and 29.2% for individual 3. FU, follow-up.
84 • MEDICAL DECISION MAKING/JAN–FEB 2009
KOFFIJBERG, RINKEL, BUSKENS
 at University of Groningen on July 13, 2009 http://mdm.sagepub.comDownloaded from 
because the detection threshold of 1% was not
exceeded. Similarly, in the second screening exami-
nation, no aneurysm was detected for individuals 2
and 3.
Extended Markov Model
In the ASTRA project, we constructed a Markov
decision model to determine the cost-effectiveness of
screening for (new) aneurysms in patients with
clipped aneurysms after subarachnoid hemorrhage.12
The decision model was used to estimate long-term
costs and effects of a screening strategy in which
patients were screened every 5 years for new aneur-
ysms, up to the age of 70 years. The cost-effectiveness
analyses showed that screening in general is not cost-
effective but that screening in patients with addition-
al risk factors may be beneficial and cost-effective. In
particular, screening was estimated to be cost-saving
and provided additional quality-adjusted life years
(QALYs) for patients with at least a 4.5 times in-
creased risk of aneurysm formation and a 4.5 times
increased risk of rupture. Within this model, the
annual risk of aneurysm formation and aneurysm
rupture was considered constant. To assess whether
variation in risks between and within individuals
over time affects the results of this model, we extend-
ed the original Markov model with these 2 variations
in risks, defined and categorized alike in the simula-
tion study (see appendix). In addition, the extended
model reflected 2 new assumptions. (1) On average,
an aneurysm can be detected only using computed
tomographic angiography (CTA) 2 years and onward
after formation. The original model used a probabil-
ity of false-negative CTA that was independent of
aneurysm size. However, in practice, aneurysms
smaller than 3 mm may easily be missed, whereas it
is unlikely that aneurysms over 5 mm will be missed
at all.18 We again used the cumulative risk of rupture
experienced by individuals as a proxy of the corre-
sponding aneurysm sizes. In the resulting model, risk
of aneurysm rupture may vary over time and between
individuals. Consequently, an aneurysm will be
detected once an individual has experienced a cumu-
lative risk of rupture equaling twice the annual risk
of rupture used in the original model. Thus, on aver-
age, the risk threshold will be exceeded after 2 years,
but individuals (temporarily) at high risk may sur-
pass the detection threshold in less than 2 years.
Conversely, for individuals at low risk, the threshold
may not be surpassed until many years have passed.
The probability of a false-negative CTA equals 1 for
aneurysms considered small and not detectable and
equals 0 for aneurysms considered large and detect-
able. In the model, both small and large aneurysms
may rupture. (2) In the year following treatment, by
definition, aneurysm formation is precluded, as well
as rupture.
We used the extended Markov model to simulate
a hypothetical cohort of 50,000 individuals. Both
the extended Markov model and the simulation
study were implemented using Mathematica (v5.2,
Wolfram Research, Inc., Champaign, Illinois).
RESULTS
Simulation Study
The expected number of instances of SAH that
may be prevented by screening is shown in Figure 2,
where the screening strategies are ranked by effective-
ness. All screening strategies result in a substantial re-
duction of the number of SAHs, regardless of the
degree of within- and between-individual variation.
However, for all strategies and regardless of the de-
gree of interindividual variation, the expected num-
ber of prevented SAH instances drops with an
increasing degree of intraindividual variation. In Fig-
ure 2A, for example, this reduction is 16% for strategy
1 when low intraindividual variation is present (no
WIV: 5934 SAHs prevented, low WIV: 5004 SAHs
prevented, a difference of 930 instances [16%]). With
high intraindividual variation, again a 16% reduction
is found (low WIV: 5004 SAHs prevented, high WIV:
4215 SAHs prevented, a difference of 789 instances
[16%]). Although for strategies less effective than
strategy 1, such as strategy 8, the reduction in abso-
lute numbers of instances prevented may be smaller
(Table 1), the relative reduction in instances prevent-
ed is still substantial. The reduction in efficiency of
screening caused by both types of variation appears
partially independent and additive (Table 1). In other
words, any intraindividual variation will add to the
effects caused by interindividual variation and vice
versa. If there is a high degree of both types of varia-
tion, the reduction in efficiency may be as high as
58% (strategy 2 in Table 1).
Extended Markov Model
After extending the Markov model with the 2
new assumptions, the predictions were similar to
those from the original model if WIV and BIV were
set to 0, which shows that the 2 additions hardly
affect the outcome. Table 2 shows the results of
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simulating cohorts of individuals in the extended
Markov model. For each category of relative risk of
rupture and formation, 9 rows show the results for
the 9 combinations of categories of BIV and WIV.
Within similar categories of BIV and increasing
WIV, the expected number of SAHs that can be pre-
vented by screening decreased, and the costs per in-
dividual increased. Within similar categories of
WIV and increasing BIV, effectiveness of screening
decreased only in the 5-fold increased risk category.
At a cost-effectiveness threshold of €20,000 per
QALY, the original and extended models lead to the
same conclusion—that is, in this case, the results ap-
peared robust. Screening appeared cost-effective for
individuals with at least a 2-fold increased risk (i.e.,
regardless of any variation between or within indi-
viduals). However, the number of instances of SAH
prevented in this group of patients may be overesti-
mated substantially when inter- and intraindividual
variation is not taken into account. If no variation is
assumed, the expected number of prevented SAHs is
5685, whereas in the presence of a high degree of
intraindividual variation, this number decreases to
4576. Thus, without taking into account intraindivi-
dual variation in risks, the number of SAH instances
prevented by screening will be overestimated by
24%. Similarly, if interindividual variation is not tak-
en into account (in the absence of intraindividual
variation), the number of SAHs prevented by screen-
ing will be overestimated by 2%. If a high degree of
both types of variation is present but not accounted
for, the number of prevented SAHs will be overesti-
mated by 29%.
DISCUSSION
Variation of disease progression within individu-
als over time reduces the efficacy of screening to a
considerable extent and decreases cost-effectiveness.
Although the effects of inter- and intraindividual
variation are not completely independent (i.e., they
do not add up), taking into account only one type
of variation still results in overestimating the yield
of screening when variation of the other type is
also present. Furthermore, the overestimation from
intraindividual variation may be similar to or even
greater than the overestimation due to interindivi-
dual variation, as in our examples.
The decreased (cost-)effectiveness of screening
strategies due to intraindividual variation in disease
progression can be explained easily. For efficiency
reasons, individuals with short periods of rapidly
growing disease should be screened often to ensure
timely detection, whereas those with (short periods
of) slowly progressing disease can be screened at lon-
ger intervals. When no intraindividual variation in
disease progression is assumed, it is possible to deter-
mine an optimal screening interval—that is, a screen-
ing strategy resulting in the lowest cost-effectiveness
ratio for low- and high-risk individuals separately.
However, if the optimal screening interval is deter-
mined using an average progression speed in the
presence of intraindividual variation in disease pro-
gression, screening procedures will be performed
at suboptimal points in time. Individuals will be
screened unnecessarily often during periods of stable
disease and too infrequently during periods with
Table 1 Fraction of the Expected 10,200 SAH Instances That May Be Prevented by Screening
Strategy 1 Strategy 2 Strategy 3 Strategy 4 Strategy 5 Strategy 6 Strategy 7 Strategy 8
Screening interval, years 2 5 2 2 5 5 2 5
Detection threshold, % risk 1 1 3 1 3 1 3 3
Period of zero risk, years 2 2 2 1 2 1 1 1
WIV BIV
No No 58 (NA) 49 (NA) 48 (NA) 44 (NA) 39 (NA) 37 (NA) 31 (NA) 28 (NA)
No Low 52 (11) 39 (19) 46 (4) 40 (8) 38 (3) 34 (7) 29 (7) 26 (8)
No High 45 (22) 32 (33) 41 (14) 38 (13) 36 (8) 32 (11) 28 (9) 24 (14)
Low No 49 (16) 32 (35) 46 (5) 34 (23) 35 (10) 33 (9) 29 (8) 26 (7)
Low Low 46 (21) 31 (37) 45 (7) 32 (28) 33 (17) 32 (12) 28 (11) 25 (10)
Low High 42 (29) 26 (46) 38 (20) 29 (34) 32 (19) 29 (20) 25 (18) 23 (16)
High No 41 (29) 28 (43) 40 (16) 28 (35) 32 (17) 31 (15) 26 (16) 23 (19)
High Low 37 (36) 24 (51) 33 (31) 24 (44) 28 (27) 28 (24) 22 (30) 21 (23)
High High 32 (44) 21 (58) 31 (36) 22 (51) 28 (28) 27 (26) 20 (36) 19 (33)
Values are in percentages. Values in parentheses are the relative reductions in the number of subarachnoid hemorrhage instances prevented compared
with the first category, in which no inter- and intraindividual variation is assumed. WIV, within-individual variation; BIV, between-individual varia-
tion; NA, not applicable.
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rapid disease progressing. The number of suboptimal
screening procedures will increase with increasing
intraindividual variation in progression, and as a con-
sequence, screening efficacy and cost-effectiveness
will decrease.
In our example of the extended Markov model,
incorporating inter- and intraindividual variation in
disease progression resulted in the same overall con-
clusion compared with the original model regarding
the cost-effectiveness of screening for intracranial
aneurysms. However, in other situations, ignoring
intraindividual variation in disease progression may
lead to different overall conclusions with respect
to the benefits of screening than accounting for
intraindividual variation in disease progression. This
can be illustrated by applying a hypothetical cost-
effectiveness threshold of €5000 per QALY in our
example. Apparent from Table 2, screening would be
deemed cost-effective for individuals with a 2-fold
increased risk if variation in risk is not taken into ac-
count (i.e., BIV=no, WIV=no, incremental cost-
effectiveness ratio [ICER]= €3336/QALY) but would
no longer be deemed cost-effective if some variation
in risk is taken into account. This illustrates that in
some cases the issue may be nontrivial. Thus, models
that do not account for intraindividual heterogeneity
may provide unrealistic results.
Although currently the supporting evidence is
limited, we feel that our results are not unique for
intracranial aneurysm development or characteris-
tics of aneurysm screening procedures. It is known,
for example, that biological variation may cause
intraindividual changes in factors such as lipid lev-
els, cell-mediated immunity, and blood flow veloci-
ties. However, these changes have not been related
to screening efficiency.1921 Instead of accounting
for intraindividual changes in risk, it is advocated to
perform repeated measurements to determine a
robust, average risk for each individual. In addition,
intraindividual variation previously has been classi-
fied as a risk factor itself for schizophrenia,22 and
variation in risk over time in individuals surviving
coronary artery bypass graft surgery has been
assessed.23 Assuming constant risk in these patients
during the postoperative period may substantially
overestimate or underestimate risk at some times.
Our study has certain limitations. The values for
the parameters WIV and BIV were chosen some-
what arbitrarily, to represent no variation and low
and high degrees of variation. This was done be-
cause no clinical data on the variation of aneurysm
growth rates in individuals were available from the
literature. Thus, in reality, the extent of the
Figure 2 The expected number of instances of subarachnoid
hemorrhage (SAH) that may be prevented by each screening strat-
egy, when the total number of expected instances of SAH is
10,200. The interindividual variation is set to (A) no, (B) low, and
(C) high for 3 degrees of intraindividual variation. Definition of
the 8 screening strategies, in terms of the screening interval,
detection threshold, and period of zero risk, is given at the top of
Table 1. WIV, within-individual variation.
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reduction in screening efficacy from intraindividual
variation in aneurysm growth rates may differ from
the results presented here. However, regardless of
the actual degree of variation, the benefits provided
by screening will be overestimated if this variation
is not taken into account.
In addition to the degree of inter- and intraindivi-
dual variation, the distribution of the intraindividual
risk over time and the fraction of individuals having a
risk that is markedly lower or higher than average in-
fluence the impact of variation on cost-effectiveness.
The impact of intraindividual variation on (cost-)
effectiveness will be highest if the variation is caused
by individuals experiencing all their risk in a very
short time period. Similarly, the impact of interindivi-
dual variation will be highest if it is caused by a very
small fraction of all individuals who, together, experi-
ence all of the total population risk.
Although the effects of heterogeneity among
individuals in their susceptibility to disease have
been assessed in many studies,36 the effects of
intraindividual variation in disease progression over
time rarely have been investigated. Our results show
that information on the distribution of inter- and intra-
individual variation in disease progression should be
taken into account when developing cost-effectiveness
models. Unless evidence supports a constant rate of
progression in all individuals, simplications with re-
spect to intraindividual heterogeneity result in overly
optimistic conclusions regarding (cost-)effectiveness of
screening programs. This bias is similar to, but par-
tially independent of, the bias caused by ignoring
interindividual heterogeneity.
APPENDIX
In the simulation model, random risk profiles were gen-
erated, with each risk profile consisting of a risk profile
Table 2 Comparison of the Screening Strategy with the No-Screening Strategy
Relative Risk of
Aneurysm Formation












1.0 No No 576 −0.01 NA 1878
No Low 590 −0.02 NA 1820
No High 617 −0.02 NA 1621
Low No 627 −0.04 NA 1733
Low Low 863 −0.06 NA 1646
Low High 916 −0.06 NA 1602
High No 718 −0.02 NA 1711
High Low 779 −0.04 NA 1699
High High 881 −0.04 NA 1621
2.0 No No −300 −0.09 3336 5685
No Low −293 −0.09 3259 5530
No High −262 −0.11 2383 4576
Low No −706 −0.10 7060 5670
Low Low −692 −0.09 7689 5453
Low High −650 −0.10 6496 4613
High No −774 −0.08 9671 5573
High Low −754 −0.08 9422 5338
High High −739 −0.10 7387 4406
5.0 No No −5711 0.04 −136,426 15,209
No Low −5458 0.04 −131,954 14,868
No High −5089 0.05 −100,964 13,011
Low No −4717 0.05 −101,630 14,898
Low Low −3677 0.04 −94,634 14,458
Low High −3365 0.04 −88,363 12,344
High No −4504 0.04 −112,337 14,114
High Low −3423 0.03 −103,005 13,454
High High −3046 0.03 −95,739 11,231
For each subgroup, results are shown for 9 combinations of inter- and intraindividual variation. For each combination, the additional costs and quality-
adjusted life years (QALYs) per individual are shown. In addition, the incremental cost-effectiveness ratio (ICER) of screening compared with no screen-
ing is shown. WIV, within-individual variation; BIV, between-individual variation; NA, not applicable.
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due to aneurysm growth and a risk profile due to aneurysm
size. Together, these 2 profiles made up the overall risk pro-
file for an individual, and both profiles accounted for 50%
of the overall risk of SAH. The profile of rupture risk due to
size was determined by the rate and duration of aneurysm
growth, and thus it was the cumulative of the growth-
related risk profile. The variation in risk was introduced
using 2 parameters: BIV (between-individual variation) and
WIV (within-individual variation). Values of WIV greater
than 0 cause risks to vary over time within individuals, and
values of BIV greater than 0 cause heterogeneity in the
absolute risk experienced by different individuals. We
investigated 3 categories of values for WIV: no variation
(value 0), low variation (value 0.15), and high variation
(value 0.5). The categories of no, low, and high variation
were also investigated for BIV with corresponding values 0,
0.5, and 2. Because the effects of WIV and BIV are not
implemented similarly, the categories of no, low, and high
variation are not based on the same values for both types of
variations. The value of WIV determines the variation in
risks that individuals experience from day to day, over the
25-year time horizon. The value of BIV, on the other hand,
determines the total variation in relative risk that is present
in the hypothetical cohort of individuals. The total risk of
aneurysm rupture in our hypothetical cohort was standar-
dized to be the same for all combinations of values of BIV
andWIV.
For both risk profiles, values were determined for each
day, over the 25-year time horizon, according to the pseudo-
code routine presented below. Note that parameter WIV is
used only in line 09, when the change in risk is determined
per day, using a random value and the risk of the preceding
day. When WIV is near 0, the risk of each day will approxi-
mately equal the risk of the preceding day, and there will be
very low variation in risks within individuals over time.
Similarly, parameter BIV is used only in line 02, when the
relative risks over the complete period are determined for all
individuals. When BIV is near 0, the sum of these relative
risks, divided by the number of individuals, will equal
1—that is, the total risk experienced will be approximately
equal for all individuals (regardless of any variation in risks
over the days that individuals may experience). In this way,
the parameters BIV and WIV independently control the de-
gree of inter- and intraindividual variation, whereas the total
risk of SAH over the entire hypothetical cohort of individu-
als remains unchanged. Thus, when individuals are not
screened to prevent SAH instances, the expected number of
events for arbitrary values of the parameters WIV and BIV is
equal to the expected number of events when the same, con-
stant, (annual) risks are used for all individuals.
The original Markov decision model was similarly ex-
tended to incorporate inter- and intraindividual variation.
Similar to the original model, the extended model used
time cycles of 1 year.
Pseudocode for the Determination of the Daily Risk of SAH, Separately for All Hypothetical
Individuals, Based on Variation between and within Individuals
01. For i= 1 To NumInd do: // Perform for all individuals
02. IndTotalRR [i]=Exp(Random(NormalDistribution
(mean= 0, sd=BIV))) // Determine the target risk per individual
03. SumTotalRR=SumTotalRR+ IndTotalRR [i]/NumInd // Determine average, overall relative risk
04. End for i.
05. For i= 1 To NumInd do: // Perform for all individuals
06. RiskGrowth [i,1]=OverallCumRisk / (25∗365) // Set risk due to growth for day 1
07. CumRiskGrowth [i,1]=RiskGrowth [i,1] // Set cumulative risk due to growth for day 1
08. For j= 2 To 25∗365 do: // Set the growth profile for day 2 and onward
09. RiskGrowth [i,j]=RiskGrowth [i, j-1]∗
Exp(Random(NormalDistribution(mean= 0, sd=WIV))) // Model the risk per day
10. CumRiskGrowth [i,j]=CumRiskGrowth [i,j]+
RiskGrowth [i,j] // Determine the cumulative risk
11. End for j.
12. TotRiskGrowth=CumRiskGrowth [i, 25∗365] // Determine the total risk due to growth
13. For j= 1 To 25∗365 do: // Normalize and scale the profiles
14. RiskGrowth [i,j]= (RiskGrowth [i,j]/TotRiskGrowth )∗ 0.5 ∗ OverallCumRisk ∗ (IndTotalRR [i] / SumTotalRR)
15. RiskSize [i,j]= (CumRiskGrowth [i,j]/TotRiskGrowth) ∗ 0.5 ∗ OverallCumRisk ∗ (IndTotalRR [i] / SumTotalRR)
16. RiskRupture [i,j]=RiskGrowth [i,j]+RiskSize [i,j]
17. End for j.
18. End for i.
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With the parameters defined as follows:
WIV: Within-individual variation or intraindividual heterogeneity
BIV: Between-individual variation or interindividual heterogeneity
NumInd: The number of individuals in the hypothetical cohort
IndTotalRR [i]: The relative risk of aneurysm formation and rupture for individual i
SumTotalRR: The average relative risks over all individuals (used for scaling)
OverallCumRisk: The cumulative overall (total) risk of aneurysm formation and rupture per patient: 0.102
RiskGrowth [i,j]: The risk of aneurysm rupture due to aneurysm growth, for individual i on day j
CumRiskGrowth [i,j]: The cumulative risk of aneurysm rupture due to aneurysm growth, for individual i on day j
TotRiskGrowth: The total risk of rupture due to aneurysm growth for a specific individual
RiskSize [i,j]: The risk of aneurysm rupture due to aneurysm size, for individual i on day j
RiskRupture [i,j]: The total risk of rupture, due to aneurysm growth and aneurysm size, for individual i on day j
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